Bone status in men with heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure

Loncar, Goran; Garfias-Veitl, Tania; Valentová, Miroslava; Vatic, Mirela; Lainščak, Mitja; Obradović, Danilo; Dschietzig, Thomas; Doehner, Wolfram; Jankowska, Ewa A.; Anker, Stefan D.; Haehling, Stephan von

doi:10.1002/ejhf.2794

Cited by 5 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors disclosed not only worse BMD parameters in every localization in HF patients, but importantly, in these patients, they found significant global and local reductions of BMD as well as worsening of Z-score over time. 11 The current issue of the Journal presents a paper by Loncar et al 12 who reported a retrospective analysis of longitudinal changes of BMD in 141 men with stable chronic HF based on four time-points DEXA scans over the follow-up of 30 months. Patients were also clinically observed for up to 8 years, and bone characteristics were correlated with blood markers and prognosis.…”

Section: Egg or Hen Dilemmamentioning

confidence: 99%

See 1 more Smart Citation

Bones in heart failure: missing piece of the body wasting puzzle

Rozentryt

Niedziela

Gasior

2023

European J of Heart Fail

View full text Add to dashboard Cite

Section: Egg or Hen Dilemmamentioning

confidence: 99%

“…The current issue of the Journal presents a paper by Loncar et al 12 . who reported a retrospective analysis of longitudinal changes of BMD in 141 men with stable chronic HF based on four time‐points DEXA scans over the follow‐up of 30 months.…”

Section: Egg or Hen Dilemmamentioning

confidence: 99%

Bones in heart failure: missing piece of the body wasting puzzle

Rozentryt

Niedziela

Gasior

2023

European J of Heart Fail

View full text Add to dashboard Cite

“…Among 47 patients undergoing a re‐evaluation of BMD, a significant reduction in BMD was observed at 30 months. Thus, an assessment of bone status might be of help in the prevention of osteoporosis in HF patients 30 …”

Section: Comorbiditiesmentioning

confidence: 99%

“…Thus, an assessment of bone status might be of help in the prevention of osteoporosis in HF patients. 30…”

mentioning

confidence: 99%

May 2023 at a glance: focus on pathophysiology, comorbidities and devices

Tomasoni

Adamo

Metra

2023

European J of Heart Fail

View full text Add to dashboard Cite

Win ratio approachThe win ratio is increasingly used as a statistical tool to include multiple variables related both with outcomes as well as symptoms and quality of life and thus gain statistical power from smaller study groups. 1,2 The EMPULSE trial evaluated the clinical benefit of empagliflozin versus placebo in 530 patients with acute heart failure (HF) after initial stabilization using the stratified win ratio approach. 2 Based on the experience from the EMPULSE trial, Pocock et al. 3 elucidated how the win ratio method works and what it means, in order to favour its use in future trials. The investigators of the EMPULSE trial were able to integrate deaths, clinical events and patient-reported outcomes into a win ratio strategy, highlighting the most meaningful clinical findings related to patients' benefits. Natriuretic peptidesBiomarkers are foundation of current management of HF. [4][5][6][7][8][9] The role of natriuretic peptides to establish the diagnosis of HF is established in international HF guidelines. 10-12 A scientific statement by three HF Societies (Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society) provides a comprehensive and updated perspective for the use of natriuretic peptides in the prognostic stratification, management and treatment of HF. 13 Pathophysiology Giannoni et al. 14 reviewed recent evidence regarding chemoreflex physiology and pathophysiology with desensitization of hyperactive chemoreceptors that is emerging as a potential therapeutic option for patients with hypertension and HF. 14 It has recently been observed that left ventricular ejection fraction (LVEF) may have a U-shaped relationship with mortality with an increase in the risk of death also in patients with a LVEF >65%. 15,16 These patients with supranormal (sn) LVEF (HFsnEF) may have peculiar characteristics compared to those with preserved ejection fraction (HFpEF), with a higher risk of events and a lower response to medical treatment, namely

show abstract

Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment

von Haehling,

Assmus,

Bekfani

et al. 2024

Clin Res Cardiol

View full text Add to dashboard Cite

The aetiology of heart failure with preserved ejection fraction (HFpEF) is heterogenous and overlaps with that of several comorbidities like atrial fibrillation, diabetes mellitus, chronic kidney disease, valvular heart disease, iron deficiency, or sarcopenia. The diagnosis of HFpEF involves evaluating cardiac dysfunction through imaging techniques and assessing increased left ventricular filling pressure, which can be measured directly or estimated through various proxies including natriuretic peptides. To better narrow down the differential diagnosis of HFpEF, European and American heart failure guidelines advocate the use of different algorithms including comorbidities that require diagnosis and rigorous treatment during the evaluation process. Therapeutic recommendations differ between guidelines. Whilst sodium glucose transporter 2 inhibitors have a solid evidence base, the recommendations differ with regard to the use of inhibitors of the renin–angiotensin–aldosterone axis. Unless indicated for specific comorbidities, the use of beta-blockers should be discouraged in HFpEF. The aim of this article is to provide an overview of the current state of the art in HFpEF diagnosis, clinical evaluation, and treatment. Graphical Abstract

show abstract

Bone status in men with heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure

Abstract: To assess bone status expressed as hip bone mineral density (BMD) in men with heart failure (HF).

Cited by 5 publications

References 42 publications

Bones in heart failure: missing piece of the body wasting puzzle

Bones in heart failure: missing piece of the body wasting puzzle

May 2023 at a glance: focus on pathophysiology, comorbidities and devices

Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment

Contact Info

Product

Resources

About